(POST10): Syncope Trial to Understand Tilt Testing or ECG Recording Tenth Prevention of Syncope Trial

Sponsor
University of Calgary (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05776810
Collaborator
(none)
144
1
1
44
3.3

Study Details

Study Description

Brief Summary

The Study To Understand Tilt Tests versus Extended Recordings (STUTTER, POST 10) will test the hypothesis that first performing a diagnostic HUT in older patients with syncope of unknown cause will provide earlier and more diagnoses than inserting an ICM.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Diagnostic Test: Head Up Tilt Table (HUT)
  • Device: Device: Implantable Loop Recorder
N/A

Detailed Description

A total of 144 patients ≥50 years old with ≥1 syncopal spell in the preceding year who lack a clear etiologic diagnosis for syncope and no clinically apparent structural heart disease will be randomized to first undergo HUT or to first receive an ICM in an open label, parallel group study. The primary outcome measure will be the establishment of a documented etiologic diagnosis of the cause of syncope, defined below. This will be a formal pragmatic study of two diagnostic strategies, designed around the PRECIS2 criteria. The key question addresses which test should be done first, and beyond that care will be left in the hands of the specialist physician with primary responsibility for assessing and managing syncope.

This is a Pragmatic Trial, which is a rigorous randomized trial method that enables the study of interventions in the real world. Pragmatic trials are designed to determine the effects of an intervention under the usual conditions in which it will be applied, in contrast to conventional explanatory biomedical trials that are designed to determine the effects of an intervention under ideal circumstances. The researcher's touchstone is usual syncope specialist management. There are 9 criteria of the PRECIS2 tool for pragmatic trials:1) similarity of eligibility criteria to usual care, 2) no extra recruitment effort, 3) similar setting to usual care, 4) similar health care organization and delivery to usual care, 5) similar flexibility to usual care, 6) similar flexibility in patient monitoring, 7) similar follow-up intensity to usual care, 8) direct relevance of primary outcome to participants, and 9) completeness of data inclusion. Each criterion is scored 1-5; the researchers provide these scores for each criterion. Study design and conduct are designed to resemble real clinical practice with its variable conduct and decision-making. The primary outcome is establishing a diagnosis by one of two recommended methods, and both methods have evidence-based criteria. the researchers will issue a brochure to remind investigators of the guidelines' criteria. Both have objective ECG criteria and tilt tests have BP criteria. Bias is a concern, and the Outcomes Adjudication Committee will adjudicate post hoc all results blindly.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
144 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single Group AssignmentSingle Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Syncope Trial to Understand Tilt Testing or ECG Recording. Tenth Prevention of Syncope
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: All eligible participants

All eligible participants are randomly assigned to one of two interventions- early Head-Up Tilt Table procedure or early Implantable Loop Recorder. The assignment is random and at a 1:1 ratio between the two strategies. Interventions: Diagnostic Test: Head Up Tilt Table (HUT) Device: Implantable Loop Recorder

Diagnostic Test: Diagnostic Test: Head Up Tilt Table (HUT)
Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study. the early HUT [protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes]

Device: Device: Implantable Loop Recorder
ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.

Outcome Measures

Primary Outcome Measures

  1. The primary outcome will be the determination of the diagnosis of the cause of syncope (PRECIS2 criterion 8, 5/5) within 2 years. [within 2 years]

Secondary Outcome Measures

  1. cost from the perspective of the health care system [Within 2 years]

  2. psychometric quality of life [Within 2 years]

  3. sex and gender, and patient preferences. [Within 2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age >50 years old

  • ≥1 syncope26 in the prior 12 months

  • diagnosis unclear after history, physical exam, and electrocardiogram

  • no apparent risk of death due to the cause of syncope

Exclusion Criteria:
  • cannot provide informed consent or attend routine follow up

  • have known left ventricular ejection fraction < 50%,or have

  • pacemaker, ICD, or ICM

  • Class I indication for permanent pacing or ICD implantation

  • hypertrophic cardiomyopathy

  • a history of myocardial infarction within 3 months prior to enrolment

  • a major chronic co-morbid medical condition that would preclude 12 months of follow-up

  • bifascicular block

  • epilepsy proven by electroencephalography

  • syncope of known cause

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Calgary Calgary Alberta Canada T2N 4Z6

Sponsors and Collaborators

  • University of Calgary

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Calgary
ClinicalTrials.gov Identifier:
NCT05776810
Other Study ID Numbers:
  • POST 10
First Posted:
Mar 20, 2023
Last Update Posted:
Mar 20, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 20, 2023